Early-stage mixed breast carcinoma found during LGI1 limbic encephalitis workup

Patient Info: Anonymized, Female | Stage I

Biomarkers: ER 95-100% positive; PR 80% positive; HER2-negative

She gradually recovered after immunotherapy for limbic encephalitis and excision of the early-stage breast tumor, and had returned to part-time work 12 months after discharge.

PubMed CentralRead more →

Breast cancer linked to a rare kidney condition believed to be cancer-related

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive; PR-positive; HER2 score 1+; Ki-67 5-10%

At the latest follow-up, she had no local or distant breast-cancer recurrence and maintained excellent performance status.

PubMed CentralRead more →

Metastatic Neuroendocrine Breast Cancer With Severe Hormone Overproduction

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER-negative, PR focally positive, HER2-negative, PIK3CA mutation

Metastatic Site: liver, bone

Died after rapid deterioration and cardiac arrest during progressive metastatic disease.

PubMed CentralRead more →

HER2-positive breast cancer with brain metastases: responding well to T-DXd

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive / HER2 IHC 3+

Metastatic Site: brain (left cerebellum, left frontal lobe, medulla)

After 14 months and 19 doses of T-DXd, brain metastases remained controlled with no symptomatic or radiological relapse and no severe T-DXd-related adverse events.

PubMed CentralRead more →

HER2-Positive Invasive Ductal Breast Cancer Treated After Chemotherapy-Related Hemorrhagic Cystitis

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive, PR-positive, HER2-positive

Under surveillance for 2 years with no signs of malignancy.

PubMed CentralRead more →

Ductal Carcinoma In Situ With Persistent Vaccine-Related Lymph Node Swelling

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive, PR-positive

Recovered uneventfully after mastectomy, with no additional cancer treatment given.

PubMed CentralRead more →

Accessory breast cancer: surgery, radiation, endocrine therapy, no recurrence

Patient Info: Anonymized, Female, 50s | Stage I

Biomarkers: ER 2+/>95%; PR 3+/>95%; HER2-negative; Ki-67 2%

As of March 2025, 26 months after surgery, she continued anastrozole and breast MRI showed no evidence of recurrence.

PubMed CentralRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Katie's Patient Story

Patient Info: Katie, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; genetic testing negative

As of February 2025, Katie was a few months beyond active treatment for Stage III ER-positive, PR-positive, HER2-negative ILC and was adjusting to maintenance therapy with Verzenio, Lupron, and Letrozole.

Lobular Breast Cancer AllianceRead more →

Stage II HR-Positive Invasive Lobular Carcinoma: Karen's Survivor Story

Patient Info: Karen, Female, 40s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative; grade 2; inherited genetic testing negative

Karen completed double mastectomy, 3 months of chemotherapy and reconstruction. She was doing well on ongoing endocrine and targeted therapy and walking 3–5 miles daily.

Lobular Breast Cancer AllianceRead more →

Stage IIIA encapsulated papillary breast carcinoma with invasion: mastectomy, axillary dissection, and anastrozole

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: ER 100%; PgR 80%; HER2 2+ by IHC with FISH negative; Ki-67 20%; initial biopsy HER2 1+

She received postoperative anastrozole alone after right mastectomy and axillary dissection; no apparent recurrence was observed 18 months after surgery.

PubMed CentralRead more →

Breast Cancer Responses During Mistletoe Extract and Intratumoral Influenza Vaccine Treatment

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: bone, lungs, pleura

After a mixed radiologic response, she declined further imaging and remained in good condition without clinical evidence of further progression.

PubMed CentralRead more →

Stage IV luminal A breast cancer: liver resection and disease-free follow-up

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: luminal A; ER-positive; PgR-positive; HER2-negative

Metastatic Site: lung, liver

Disease-free after R0 hepatic segmentectomy for breast cancer liver metastasis, with May 2021 MRI showing no remaining liver nodules while she continued maintenance letrozole and goserelin.

PubMed CentralRead more →

Stage 4 HR-positive breast cancer: stable disease on ribociclib

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: left iliac bone

Metastatic HR-positive, HER2-negative breast cancer remained without progression as of October 2024 while she continued ribociclib 400 mg plus letrozole after SBRT to a left iliac bone metastasis.

PubMed CentralRead more →

Stage I HR-Positive Invasive Lobular Carcinoma: Janelle's Patient Story

Patient Info: Janelle, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative

As of December 2024, Janelle was living with a recent Stage IA ER-positive, PR-positive, HER2-negative lobular carcinoma diagnosis and using her research background to advocate for more inclusive ILC information and studies.

Lobular Breast Cancer AllianceRead more →

Stage IV luminal B breast cancer with liver, bone, and bone marrow metastases

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER 90% positive; PR 20% positive; HER2-negative; Ki-67 60%; luminal B

Metastatic Site: liver, bone, bone marrow

The patient had marked clinical and hematologic improvement on leuprorelin, letrozole, ribociclib, and zoledronic acid, with sustained complete remission reported for 4 months from September to December 2023 and monthly follow-up advised.

PubMed CentralRead more →

Breast Cancer and a Separate Intrahepatic Cholangiocarcinoma in a 35-Year-Old Woman

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-positive, PR-positive, HER2/CerbB-2 positive

Breast-cancer care continued with postoperative endocrine maintenance while a separate primary intrahepatic cholangiocarcinoma required additional treatment.

PubMed CentralRead more →

A Separate Early-Stage Breast Cancer Found During Treatment for Metastatic Adenoid Cystic Carcinoma

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive, PR-positive, HER2-negative

The separate early-stage hormone-receptor-positive breast cancer remained untreated while care shifted to best supportive care for progressive metastatic adenoid cystic carcinoma.

PubMed CentralRead more →

Hormone receptor-positive breast cancer metastatic to the pituitary: surgery and disease-free follow-up

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER 2+; PR 1+; HER2 0; GATA3 positive; CA125 elevated

Metastatic Site: pituitary

Disease-free 11 months after surgical resection of pituitary metastasis from prior hormone receptor-positive, HER2-negative breast cancer, with postoperative recovery supported by antibiotics, hormone replacement/supportive therapy, and electrolyte management.

PubMed CentralRead more →

Severe Corneal Injury After Trastuzumab for Metastatic HER2-Positive Breast Cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-positive

Metastatic Site: lungs, spine, left adrenal gland, calvarium, orbit,…

She was living with widespread metastatic breast cancer when trastuzumab was stopped because of severe eye toxicity.

PubMed CentralRead more →

Anna’s Triple-Positive Breast Cancer Story

Patient Info: Anna, Female, Under 40

Biomarkers: ER-positive, PR-positive and HER2-positive

Anna completed surgery, chemotherapy and radiation and continued to navigate the effects of hormone therapy, early menopause and fertility loss.

The Patient StoryRead more →

HR-Positive Breast Cancer: Anna's Survivor Story

Patient Info: Anna, Female, Under 40

Biomarkers: ER-positive; PR-positive; HER2-positive

As of October 2024, Anna was about 7 years from diagnosis and described long-term survivorship after surgery, chemotherapy, radiation, biologic treatment, and tamoxifen-related mental-health effects.

The Patient StoryRead more →

Stage II HER2-Positive Breast Cancer With Fever and a Reversible Brain MRI Lesion After Radiotherapy

Patient Info: Anonymized, Female, Under 40 | Stage II

Biomarkers: ER-positive, PR-positive, HER2-positive

After radiotherapy, fever, neutropenia, headache, and a reversible splenial brain lesion resolved with supportive and antibiotic treatment during her postoperative breast-cancer treatment course.

PubMed CentralRead more →

Hormone receptor-positive invasive lobular carcinoma treated with neoadjuvant chemotherapy

Patient Info: Anonymized, Female, 50s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative; Ki-67 20%

Three-month follow-up showed the biopsy-related pseudoaneurysm had thrombosed and regressed, clearing the way for planned neoadjuvant chemotherapy and surgery; cancer response after planned treatment was not yet available.

PubMed CentralRead more →

Stage 1 invasive ductal breast cancer: nipple-preserving mastectomy with reconstruction

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative; Ki-67 28%

No signs of recurrence 20 months after nipple-preserving mastectomy, sentinel node biopsy, immediate reconstruction, adjuvant chemotherapy, and endocrine therapy for ER-positive, PR-positive, HER2-negative invasive ductal breast cancer.

PubMed CentralRead more →